Latest Adalimumab Stories
Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif., Oct.
-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators
Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass.,
Rheumatologists Report that the Vast Majority of RA Patients Who are Candidates for Biologic Treatment Receive a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass.,
The Imminent Entry of Biosimilars Will Constrain Sales of Branded Biologics and Premium-Priced Emerging Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept.
- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark,
TNF-Alpha Inhibitors--Including Sales Leader Humira--Accounted for Over 90 Percent of the Psoriatic Arthritis Market, According to Findings from Decision Resources Group BURLINGTON, Mass.,
Company To Pursue Next Stage of Development REDWOOD CITY, Calif., Aug. 14, 2014 /PRNewswire/ -- Coherus BioSciences, Inc.
Supports progression of this first-in-class anti-TLR4 monoclonal antibody into clinical proof of concept study as a potential personalized medicine for rheumatoid arthritis GENEVA, August
Nearly half a million dollars given to early-career physicians to study psoriatic disease PORTLAND, Ore., July 17, 2014 /PRNewswire-USNewswire/ -- Twelve residents and medical students each
- The act of sweetening by admixture of some saccharine substance.